Cytomx Therapeutics Stock Performance
| CTMX Stock | USD 2.39 0.04 1.65% |
CytomX Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 6.03, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CytomX Therapeutics will likely underperform. Use CytomX Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on CytomX Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CytomX Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, CytomX Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.67 | Five Day Return 0.41 | Year To Date Return 129.25 | Ten Year Return (81.16) | All Time Return (81.16) |
1 | CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 CTMX Stock News | 05/05/2025 |
2 | CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody ... | 05/12/2025 |
3 | CytomX Therapeutics Price Target Doubled Following Promising Trial Results CTMX Stock News | 05/15/2025 |
4 | CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA in Patients with Metastatic Melanoma | 05/19/2025 |
5 | HC Wainwright Has Bearish Forecast for CTMX Q2 Earnings | 05/21/2025 |
6 | Acquisition by Ashworth Alan of 38000 shares of CytomX Therapeutics at 2.82 subject to Rule 16b-3 | 06/11/2025 |
7 | Disposition of 55511 shares by Mccarthy Sean A. of CytomX Therapeutics at 2.6889 subject to Rule 16b-3 | 06/16/2025 |
8 | Disposition of 10614 shares by Christopher Ogden of CytomX Therapeutics at 2.6889 subject to Rule 16b-3 | 06/17/2025 |
9 | What analysts say about CytomX Therapeutics Inc. stock - Free Trading Strategy Suggestions - jammulinksnews.com | 07/22/2025 |
| Begin Period Cash Flow | 18.1 M | |
| Total Cashflows From Investing Activities | 99.7 M |
CytomX Therapeutics Relative Risk vs. Return Landscape
If you would invest 71.00 in CytomX Therapeutics on April 25, 2025 and sell it today you would earn a total of 172.00 from holding CytomX Therapeutics or generate 242.25% return on investment over 90 days. CytomX Therapeutics is currently generating 2.9601% in daily expected returns and assumes 17.6593% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than CytomX, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CytomX Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytomX Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CytomX Therapeutics, and traders can use it to determine the average amount a CytomX Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1676
| Best Portfolio | Best Equity | |||
| Good Returns | CTMX | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 17.66 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.96 actual daily | 59 59% of assets have lower returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average CytomX Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CytomX Therapeutics by adding it to a well-diversified portfolio.
CytomX Therapeutics Fundamentals Growth
CytomX Stock prices reflect investors' perceptions of the future prospects and financial health of CytomX Therapeutics, and CytomX Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CytomX Stock performance.
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.44 % | ||||
| Current Valuation | 304.79 M | ||||
| Shares Outstanding | 157.54 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 15.03 X | ||||
| Price To Sales | 2.55 X | ||||
| Revenue | 138.1 M | ||||
| Gross Profit | 147.56 M | ||||
| EBITDA | 26.76 M | ||||
| Net Income | 31.87 M | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 9.38 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (86.23 M) | ||||
| Earnings Per Share | 0.48 X | ||||
| Market Capitalization | 376.53 M | ||||
| Total Asset | 120.53 M | ||||
| Retained Earnings | (691.58 M) | ||||
| Working Capital | 21.53 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
About CytomX Therapeutics Performance
Evaluating CytomX Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if CytomX Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CytomX Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.27 | 0.28 | |
| Return On Capital Employed | 0.72 | 0.76 | |
| Return On Assets | 0.26 | 0.28 | |
| Return On Equity | (69.89) | (66.39) |
Things to note about CytomX Therapeutics performance evaluation
Checking the ongoing alerts about CytomX Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CytomX Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CytomX Therapeutics is way too risky over 90 days horizon | |
| CytomX Therapeutics appears to be risky and price may revert if volatility continues | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (86.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: What analysts say about CytomX Therapeutics Inc. stock - Free Trading Strategy Suggestions - jammulinksnews.com |
- Analyzing CytomX Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CytomX Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CytomX Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CytomX Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CytomX Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CytomX Therapeutics' stock. These opinions can provide insight into CytomX Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.